Mezzion Pharma Statistics

Total Valuation

Mezzion Pharma has a market cap or net worth of KRW 856.95 billion. The enterprise value is 823.69 billion.

Market Cap	856.95B
Enterprise Value	823.69B

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Mezzion Pharma has 29.96 million shares outstanding. The number of shares has increased by 8.37% in one year.

Current Share Class	n/a
Shares Outstanding	29.96M
Shares Change (YoY)	+8.37%
Shares Change (QoQ)	-0.33%
Owned by Insiders (%)	9.59%
Owned by Institutions (%)	5.97%
Float	21.54M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	60.51
PB Ratio	15.94
P/TBV Ratio	16.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-57.91
EV / Sales	58.51
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-41.33

Financial Position

The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.03.

Current Ratio	2.57
Quick Ratio	1.86
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.07
Interest Coverage	-38.73

Financial Efficiency

Return on equity (ROE) is -24.18% and return on invested capital (ROIC) is -13.81%.

Return on Equity (ROE)	-24.18%
Return on Assets (ROA)	-10.13%
Return on Invested Capital (ROIC)	-13.81%
Return on Capital Employed (ROCE)	-24.84%
Revenue Per Employee	828.05M
Profits Per Employee	-836.65M
Employee Count	17
Asset Turnover	0.17
Inventory Turnover	1.73

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.13% in the last 52 weeks. The beta is 0.52, so Mezzion Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	-25.13%
50-Day Moving Average	30,390.00
200-Day Moving Average	33,284.00
Relative Strength Index (RSI)	43.19
Average Volume (20 Days)	89,457

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mezzion Pharma had revenue of KRW 14.08 billion and -14.22 billion in losses. Loss per share was -478.51.

Revenue	14.08B
Gross Profit	2.49B
Operating Income	-13.59B
Pretax Income	-13.63B
Net Income	-14.22B
EBITDA	-12.47B
EBIT	-13.59B
Loss Per Share	-478.51

Full Income Statement

Balance Sheet

The company has 34.73 billion in cash and 1.46 billion in debt, giving a net cash position of 33.26 billion or 1,110.16 per share.

Cash & Cash Equivalents	34.73B
Total Debt	1.46B
Net Cash	33.26B
Net Cash Per Share	1,110.16
Equity (Book Value)	53.76B
Book Value Per Share	1,794.56
Working Capital	30.78B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -19.19 billion and capital expenditures -744.71 million, giving a free cash flow of -19.93 billion.

Operating Cash Flow	-19.19B
Capital Expenditures	-744.71M
Free Cash Flow	-19.93B
FCF Per Share	-665.16

Full Cash Flow Statement

Margins

Gross margin is 17.69%, with operating and profit margins of -96.52% and -101.04%.

Gross Margin	17.69%
Operating Margin	-96.52%
Pretax Margin	-96.81%
Profit Margin	-101.04%
EBITDA Margin	-88.60%
EBIT Margin	-96.52%
FCF Margin	n/a

Dividends & Yields

Mezzion Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.37%
Shareholder Yield	-8.37%
Earnings Yield	-1.66%
FCF Yield	-2.33%

Stock Splits

The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.

Last Split Date	Apr 5, 2022
Split Type	Forward
Split Ratio	3

Scores

Mezzion Pharma has an Altman Z-Score of 29.77.

Altman Z-Score	29.77
Piotroski F-Score	n/a